ASİMPLEX 250 MG LYOPHILIZED POWDER FOR SOLUTION FOR INFUSION

ASİMPLEX 250 MG LYOPHILIZED POWDER FOR SOLUTION FOR INFUSION
Product Description

Herpes simplex infections in immunosuppressed patients: ASİMPLEX is indicated for the treatment of initial and recurrent cutaneous and mucosal herpes simplex (HSV1 and HSV2) in immunocompromised individuals and immunosuppressed patients. In initial infection of genital herpes: ASİMPLEX is indicated for the treatment of severe initial genital herpes in the non-immunocompromised patients. Herpes simplex encephalitis: ASİMPLEX is indicated for the treatment of Herpes simplex encephalitis. Neonatal Herpes simplex virus infection: ASİMPLEX is indicated for the treatment of neonatal herpes infections. Varicella zoster infections in immunosuppressed patients: ASİMPLEX is indicated for the treatment of Herpes zoster(zona) infections in immunocompromised individuals and immunosuppressed patients. 

Polifarma

  • Country/Region:
    Türkiye
  • On CPHI since:
    2015
  • Certificates:
    3
  • Employees:
    1000 - 4999
Company types
Pharmaceutical company
Primary activities
Animal Health
Finished Formulation products Distributor/Buyer
Laboratory, Analytical, Biotechnology Equipment
Out-licensing specialist
Pharmaceutical Company (generic finished products)
Pharmaceutical Company (innovator finished products)
Transport/Logistics/Distribution
Specifications
  • CAS Registry Number
    3
  • Supplied from
    Türkiye

Polifarma

  • Country/Region:
    Türkiye
  • On CPHI since:
    2015
  • Certificates:
    3
  • Employees:
    1000 - 4999
Company types
Pharmaceutical company
Primary activities
Animal Health
Finished Formulation products Distributor/Buyer
Laboratory, Analytical, Biotechnology Equipment
Out-licensing specialist
Pharmaceutical Company (generic finished products)
Pharmaceutical Company (innovator finished products)
Transport/Logistics/Distribution

More Products from Polifarma (60)

Polifarma resources (2)